Effects of pegylated interferon ? on fibrinolytic parameters in patients with chronic hepatitis C

Interferon (IFN) interacts with endothelial cells and modulates the functions of these cells. In our study, we aimed to determine the effects of treatment with pegylated IFN- ? (peg-IFN-?) on fibrinolytic parameters in patients with chronic hepatitis C. Fifteen patients with chronic hepatitis C were treated with peg-IFN- ? once per week plus daily oral ribavirin. Euglobulin lysis time (ELT), plasma levels of d-dimer, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI) were determined before treatment, 2 weeks, 1 month, and 3 months after the initiation of the treatment. Plasma levels of t-PA increased significantly 1 month and 3 months after the treatment (P <.05). The PAI-1 and TAFI levels in 2 weeks, 1 month and 3 months after treatment were not statistically different as compared with pretreatment levels (P >.05) No significant difference in plasma d-dimer levels was observed during peg-IFN- ? treatment (P >.05). There was a significant decrease in ELT 1 month and 3 months after the treatment (P <.05). Our results indicated that treatment with peg-IFN- ? may be associated with enhanced fibrinolysis, © SAGE Publications 2011.

Yazar Gokmen A.
Ustundag Y.
Oztoprak N.
Aydemir S.
Tekin I.O.
Cakal B.
Kiran S.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/5512
Tek Biçim Adres 10.1177/1076029610371475
Konu Başlıkları chronic viral hepatitis
fibrinolysis
interferon
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
Dergi Adı Clinical and Applied Thrombosis/Hemostasis
Dergi Cilt Bilgisi 17
Dergi Sayısı 5
Sayfalar 449 - 453
Yayın Yılı 2011
Eser Adı
[dc.title]
Effects of pegylated interferon ? on fibrinolytic parameters in patients with chronic hepatitis C
Yazar
[dc.contributor.author]
Gokmen A.
Yazar
[dc.contributor.author]
Ustundag Y.
Yazar
[dc.contributor.author]
Oztoprak N.
Yazar
[dc.contributor.author]
Aydemir S.
Yazar
[dc.contributor.author]
Tekin I.O.
Yazar
[dc.contributor.author]
Cakal B.
Yazar
[dc.contributor.author]
Kiran S.
Yayın Yılı
[dc.date.issued]
2011
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Interferon (IFN) interacts with endothelial cells and modulates the functions of these cells. In our study, we aimed to determine the effects of treatment with pegylated IFN- ? (peg-IFN-?) on fibrinolytic parameters in patients with chronic hepatitis C. Fifteen patients with chronic hepatitis C were treated with peg-IFN- ? once per week plus daily oral ribavirin. Euglobulin lysis time (ELT), plasma levels of d-dimer, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI) were determined before treatment, 2 weeks, 1 month, and 3 months after the initiation of the treatment. Plasma levels of t-PA increased significantly 1 month and 3 months after the treatment (P <.05). The PAI-1 and TAFI levels in 2 weeks, 1 month and 3 months after treatment were not statistically different as compared with pretreatment levels (P >.05) No significant difference in plasma d-dimer levels was observed during peg-IFN- ? treatment (P >.05). There was a significant decrease in ELT 1 month and 3 months after the treatment (P <.05). Our results indicated that treatment with peg-IFN- ? may be associated with enhanced fibrinolysis, © SAGE Publications 2011.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
chronic viral hepatitis
Konu Başlıkları
[dc.subject]
fibrinolysis
Konu Başlıkları
[dc.subject]
interferon
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
1076-0296
İlk Sayfa Sayısı
[dc.identifier.startpage]
449
Son Sayfa Sayısı
[dc.identifier.endpage]
453
Dergi Adı
[dc.relation.journal]
Clinical and Applied Thrombosis/Hemostasis
Dergi Sayısı
[dc.identifier.issue]
5
Dergi Cilt Bilgisi
[dc.identifier.volume]
17
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1177/1076029610371475
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/5512
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
16
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
06 Nisan 2024 21:13
Google Kontrol
Tıklayınız
treatment levels months peg-IFN- significant plasma d-dimer fibrinolysis plasminogen hepatitis activator inhibitor chronic patients significantly associated enhanced increased Plasma initiation Publications indicated results pretreatment observed during decrease compared different statistically difference Interferon before (peg-IFN-?) pegylated
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms